Abcellera Biologics Inc (ABCL)

$6.17 +0.44 (7.68%)
Market Cap 1.75B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 9,333,300
Avg Vol 6,431,942
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 97%
Beta 1.02
Analysts Strong Sell
Price Target $10.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
Stocktradesmoon
Stocktradesmoon May. 30 at 7:15 PM
$ABCL It seems that the likelihood of success for ABCL635's Phase 2 is increasingly becoming a reality, albeit cautiously, for the following two reasons. During the last earnings call, Sarah Noonberg hinted that they are preparing for Phase 3. Cautiously, it appears that the management team is placing significant weight on the possibility of Phase 2 success. The part where Noonberg said, “I doubt that we are going to need to do that” — regarding whether regulators might require additional capacity testing in Phase 3, but she suggested it probably won't be necessary, which implies they are already thinking concretely about late-stage clinical design. “We have already begun planning for next steps” — explicitly stating that they've already started planning for Phase 3, even though Phase 2 results aren't out yet. Finally, it's reasonable to suspect that the Absci management team might already know the initial results of ABCL635's Phase 2 and is preparing for the next steps.
0 · Reply
BinaryLogic
BinaryLogic May. 30 at 6:08 PM
$ABCL [Again] The Company continues to advance multiple concurrent products in its pipeline. ABCL635 (menopause) Phs-1 data showed good efficacy and tolerability, now with Phs-2 anticipated Q3-2026. Other drug products remain under development, progressing. $655M Liquidity against $40-45M quarterly burn rate allows 3-4YR cash runway. The stock is reaching Overbought on 1YR Daily and key resistance $6.25-6.50, so be aware of the situation. https://www.stocktitan.net/news/ABCL/ab-cellera-reports-q1-2026-business-results-announces-positive-tubxday3tzp6.html
0 · Reply
MorganHoratio
MorganHoratio May. 30 at 5:51 PM
The following are the returns on a portion of our current stock holdings, which account for only one-fifth of our total portfolio. $SOFI +169.69% $ABCL +118.25% $TSLA +92.57% $QS +81.77% $NVDA +78.89% While $NVDA remains the undisputed infrastructure toll-booth, the real alpha in this portfolio comes from front-running crucial structural inflections: The TSLA Re-rating: Following consecutive regulatory green lights for Full Self-Driving (FSD) across the EU and accelerating expansion in China this May, Tesla is aggressively shedding its legacy EV car-maker skin to be valued as a pure-play autonomous AI powerhouse. Fintech & Deep-Tech Symbiosis: $SOFI staged a textbook institutional V-shaped reversal after the market irrationally sold off its record-breaking earnings, while $QS and $ABCL prove that smart money is heavily rewarding high-elasticity innovation curves. This is exactly how you capture multi-bagger gains—by owning the literal inflection points of modern productivity.
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 30 at 5:11 PM
$ABCL $ABCL is awakening … 🌋 looking explosive going into next week 📈 MASSIVE upside potential IMO highest weekly close in 148 weeks Hope, you took your position and are prepared … THIS may be the next TenBagger after $MU The setup was great then, but today’s setup looks even more interesting. Jefferies conference participation next week June 4 From here, I continue to expect a move above $7.90 Something I’ve noticed during my charting earlier this morning 👀 $ABCL currently has a cup and handle WITHIN a larger cup and handle I could really do with a cuppa ☕ It was under $6 when I initially spotted the first cup and handle. The spring is coiled..
0 · Reply
Rastafari
Rastafari May. 30 at 3:47 PM
$ABCL Just the beginning! Once the data comes out in Q3, this thing will be over $20 by the end of the year!
0 · Reply
tradersunion353
tradersunion353 May. 30 at 2:18 PM
$ABCL For love of real investor not the one who are married to this stock like Demamp and other.. Investors want to see this hitting and staying above $8 before phase 2 data please. ABCL enough of your tantrums for 5 years. Time to make money for investors
0 · Reply
wgilus69
wgilus69 May. 30 at 3:49 AM
$ABCL nice! higher
0 · Reply
N2Deeeep
N2Deeeep May. 30 at 3:11 AM
$ABCL Long time coming with this one
0 · Reply
SultanK
SultanK May. 30 at 1:21 AM
$ABCL With volume going up, short ratio is now down to may be 5 days.. Interesting..
0 · Reply
UncleTomFlorida
UncleTomFlorida May. 29 at 9:13 PM
$ABCL Reached well over critical mass for $ABCL today. It’s now sufficiently established to become self sustaining. Of course, the markets being the markets the stock could go south again. But given no negative change to the fundamentals, there is no need to do anything other than lean back and enjoy the show.
2 · Reply
Latest News on ABCL
AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 16 days ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 18 days ago

AbCellera price target raised to $8 from $7 at Stifel

AbCellera Biologics Q1 Earnings Call Highlights

May 11, 2026, 7:08 PM EDT - 18 days ago

AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 18 days ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 18 days ago

AbCellera Biologics Earnings release: Q1 2026

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 18 days ago

AbCellera Biologics Quarterly report: Q1 2026

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 18 days ago

AbCellera Biologics Slides: Q1 2026

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 11, 2026, 4:05 PM EDT - 18 days ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 7, 2026, 4:05 PM EDT - 22 days ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 25 days ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 weeks ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 weeks ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 1:30 PM EDT - 5 weeks ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 20, 2026, 9:00 AM EDT - 5 weeks ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 7 weeks ago

AbCellera initiated with a Buy at JonesResearch

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 1, 2026, 4:05 PM EDT - 2 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 17, 2026, 4:30 PM EDT - 2 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 3 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Annual report: Q4 2025

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings release: Q4 2025

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Slides: Q4 2025

AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 3 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 3 months ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 4 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 4 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 4 months ago

AbCellera Biologics Slides: Corporate presentation

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

2026-01-12T14:36:23.000Z - 4 months ago

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 4 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

2025-12-18T14:20:19.000Z - 5 months ago

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

BRKR

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 5 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 6 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 6 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 7 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 7 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera downgraded to Market Perform from Outperform at Leerink

2025-11-07T11:16:20.000Z - 7 months ago

AbCellera downgraded to Market Perform from Outperform at Leerink

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Quarterly report: Q3 2025

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings release: Q3 2025

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Slides: Q3 2025

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 7 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera appoints Sarah Noonberg as Chief Medical Officer

2025-09-10T13:20:54.000Z - 9 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 9 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 9:30 AM EDT - 9 months ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

AbCellera doses first participants in Phase 1 trial of ABCL575

2025-08-27T13:20:26.000Z - 9 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 9 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera price target raised to $7 from $5 at BMO Capital

2025-08-08T13:26:29.000Z - 10 months ago

AbCellera price target raised to $7 from $5 at BMO Capital

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Quarterly report: Q2 2025

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings release: Q2 2025

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Slides: Q2 2025

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 10 months ago

AbCellera Biologics Slides: Corporate Presentation

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera assumed with an Outperform at Leerink

2025-07-07T10:40:33.000Z - 11 months ago

AbCellera assumed with an Outperform at Leerink

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 11:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2024

AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2024

AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2024

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 3:20 PM EDT - 2 years ago

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024

AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024

AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024

AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

Apr 16, 2024, 10:00 AM EDT - 2 years ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

AbCellera Biologics Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 20, 2024, 11:15 AM EDT - 2 years ago

AbCellera Biologics Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Stocktradesmoon
Stocktradesmoon May. 30 at 7:15 PM
$ABCL It seems that the likelihood of success for ABCL635's Phase 2 is increasingly becoming a reality, albeit cautiously, for the following two reasons. During the last earnings call, Sarah Noonberg hinted that they are preparing for Phase 3. Cautiously, it appears that the management team is placing significant weight on the possibility of Phase 2 success. The part where Noonberg said, “I doubt that we are going to need to do that” — regarding whether regulators might require additional capacity testing in Phase 3, but she suggested it probably won't be necessary, which implies they are already thinking concretely about late-stage clinical design. “We have already begun planning for next steps” — explicitly stating that they've already started planning for Phase 3, even though Phase 2 results aren't out yet. Finally, it's reasonable to suspect that the Absci management team might already know the initial results of ABCL635's Phase 2 and is preparing for the next steps.
0 · Reply
BinaryLogic
BinaryLogic May. 30 at 6:08 PM
$ABCL [Again] The Company continues to advance multiple concurrent products in its pipeline. ABCL635 (menopause) Phs-1 data showed good efficacy and tolerability, now with Phs-2 anticipated Q3-2026. Other drug products remain under development, progressing. $655M Liquidity against $40-45M quarterly burn rate allows 3-4YR cash runway. The stock is reaching Overbought on 1YR Daily and key resistance $6.25-6.50, so be aware of the situation. https://www.stocktitan.net/news/ABCL/ab-cellera-reports-q1-2026-business-results-announces-positive-tubxday3tzp6.html
0 · Reply
MorganHoratio
MorganHoratio May. 30 at 5:51 PM
The following are the returns on a portion of our current stock holdings, which account for only one-fifth of our total portfolio. $SOFI +169.69% $ABCL +118.25% $TSLA +92.57% $QS +81.77% $NVDA +78.89% While $NVDA remains the undisputed infrastructure toll-booth, the real alpha in this portfolio comes from front-running crucial structural inflections: The TSLA Re-rating: Following consecutive regulatory green lights for Full Self-Driving (FSD) across the EU and accelerating expansion in China this May, Tesla is aggressively shedding its legacy EV car-maker skin to be valued as a pure-play autonomous AI powerhouse. Fintech & Deep-Tech Symbiosis: $SOFI staged a textbook institutional V-shaped reversal after the market irrationally sold off its record-breaking earnings, while $QS and $ABCL prove that smart money is heavily rewarding high-elasticity innovation curves. This is exactly how you capture multi-bagger gains—by owning the literal inflection points of modern productivity.
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 30 at 5:11 PM
$ABCL $ABCL is awakening … 🌋 looking explosive going into next week 📈 MASSIVE upside potential IMO highest weekly close in 148 weeks Hope, you took your position and are prepared … THIS may be the next TenBagger after $MU The setup was great then, but today’s setup looks even more interesting. Jefferies conference participation next week June 4 From here, I continue to expect a move above $7.90 Something I’ve noticed during my charting earlier this morning 👀 $ABCL currently has a cup and handle WITHIN a larger cup and handle I could really do with a cuppa ☕ It was under $6 when I initially spotted the first cup and handle. The spring is coiled..
0 · Reply
Rastafari
Rastafari May. 30 at 3:47 PM
$ABCL Just the beginning! Once the data comes out in Q3, this thing will be over $20 by the end of the year!
0 · Reply
tradersunion353
tradersunion353 May. 30 at 2:18 PM
$ABCL For love of real investor not the one who are married to this stock like Demamp and other.. Investors want to see this hitting and staying above $8 before phase 2 data please. ABCL enough of your tantrums for 5 years. Time to make money for investors
0 · Reply
wgilus69
wgilus69 May. 30 at 3:49 AM
$ABCL nice! higher
0 · Reply
N2Deeeep
N2Deeeep May. 30 at 3:11 AM
$ABCL Long time coming with this one
0 · Reply
SultanK
SultanK May. 30 at 1:21 AM
$ABCL With volume going up, short ratio is now down to may be 5 days.. Interesting..
0 · Reply
UncleTomFlorida
UncleTomFlorida May. 29 at 9:13 PM
$ABCL Reached well over critical mass for $ABCL today. It’s now sufficiently established to become self sustaining. Of course, the markets being the markets the stock could go south again. But given no negative change to the fundamentals, there is no need to do anything other than lean back and enjoy the show.
2 · Reply
Quadruple_Double
Quadruple_Double May. 29 at 8:03 PM
$ABCL see you on Monday. Enjoy your weekend folks !
0 · Reply
Reactor_Rebel
Reactor_Rebel May. 29 at 8:01 PM
$ABCL monday we fly
0 · Reply
freedomtrader6
freedomtrader6 May. 29 at 7:57 PM
$ABCL Crazy to think $ABCL spent most of the year sitting around $3 while almost nobody cared. At those levels, you literally could’ve bought 2 shares for the price of 1 today That’s why I keep saying the market often rewards people who focus on exceptional businesses instead of obsessing over whether a stock is “popular” at the moment. Most people only become interested AFTER the chart goes vertical The funny part about investing is that the best opportunities usually feel boring, ignored, or even uncomfortable before they become obvious to everyone else
3 · Reply
Odoji
Odoji May. 29 at 7:54 PM
$ABCL 💉
1 · Reply
freedomtrader6
freedomtrader6 May. 29 at 7:53 PM
$ABCL Crazy to think··· $ABCL spent most of the year sitting around $3 while almost nobody cared. At those levels, you literally could’ve bought 2 shares for the price of 1 today That’s why I keep saying the market often rewards people who focus on exceptional businesses instead of obsessing over whether a stock is “popular” at the moment. Most people only become interested AFTER the chart goes vertical The funny part about investing is that the best opportunities usually feel boring, ignored, or even uncomfortable before they become obvious to everyone else
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 29 at 7:20 PM
$ABCL God, Bless the shorts with patience as they refresh their screens, waiting for the drop that only rises higher. Let them embrace the green tide, whether they like it or not. Amen 🙏🌊📈 $ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 29 at 7:18 PM
$ABCL I wouldn’t want to go into this weekend without any $ABCL shares 👀😉 I actually added more. Next week will be fun
0 · Reply
tranq19
tranq19 May. 29 at 7:09 PM
$ABCL look at the chart and volume today, big run up to 6.23 on big volume buys, drifting lower on low volume
0 · Reply
DeMampCamp
DeMampCamp May. 29 at 7:06 PM
$ABCL Welcome back to the board, dummy, you finally sell for a loss and now coming back to show your ignorance once again?
1 · Reply
Stocktradesmoon
Stocktradesmoon May. 29 at 7:05 PM
$ABCL I just bought more shares possible news heading into next week June 4th Jeffries conference
1 · Reply
DeMampCamp
DeMampCamp May. 29 at 7:03 PM
$ABCL Going to be an all out battle to keep this above $6 going into close, a ton of short term (fake longs) traders are going to take their profits not wanting to hold into the weekend!
1 · Reply
Bgggggggie
Bgggggggie May. 29 at 6:45 PM
$ABCL lol, this isnt worth more than a buck, super high cash burn and nothing to show for it
1 · Reply